MS and Demyelinating Disorders

An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.

Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Patricia Bobryk, MHS, PT, MSCS, ATP.

More than 80% of those with NMOSD experienced disease relapse 6 months after discontinuation of immunosuppressive therapy.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]

Doug and Kim, patients with neuromyelitis optica spectrum disorders, describe the types of symptoms that prompted each of them to seek an evaluation by a neurologist for an eventual diagnosis of a neuromyelitis optica spectrum disorder.

Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.

Lisa Donahue PT, MPT, NCS, the director of Clinical Services at Evolution Devices, offered details about the EvoWalk platform, its potential in neurorehabilitation efforts, and its future clinical availability.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.

Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.

With the field of multiple sclerosis care focusing on the importance of patient-reported outcomes and shared decision-making, the physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists offered commentary.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging provided thoughts on artificial intelligence’s role in neuroimaging and treating multiple sclerosis.

Joshua Katz, MD, commented on the possibility of an extra vaccine dose for patients with MS and experts’ hope to improve antibody response among the immunocompromised.

The division chief of vascular neurology at the University of Utah discussed the misperceptions surrounding the field of neurology, as well as the importance of increasing fellowship training.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided thoughts on the trending topics within the neuroimaging space.

Get the latest news in neuromyelitis optica spectrum disorder, with data updates and expert insights, all in one place from the NeurologyLive team.

The division chief of vascular neurology at the University of Utah discussed the driving force behind the national shortage of neurologists and its effect on patient care.

Amid an ongoing national shortage of clinicians who treat neurologic diseases like MS, the cochair of the International Organization of MS Rehabilitation Therapists discussed the availability of rehabilitation professionals for patients.

Here's what is coming soon to NeurologyLive.

The physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists spoke to the current standards of rehabilitative care among patients with multiple sclerosis.

Jennifer Majersik, MD, MS, commented on how the AAN, as well as current neurologists and specialists, can help generate interest in the field of neurology to meet patient needs.